For example, in a study of transcriptome profiles in pediatric AML by Shiba et al. [30], 30% (9/30) of AML cases with t(9;11)(p21;q23)/KMT2A::MLLT3, representing 50% of all KMT2A (MLL) rearrangement (KMT2A-R) AML cases in their cohort, and over 50% of cases with acute megakaryoblastic leukemia (AML with FAB-M7) overexpress MECOM but without 3q26.2/MECOM-R. This evidence concerns the gene MECOM and acute megakaryoblastic leukemia.